Debt-to-equity of Evofem Biosciences, Inc. from 30 Sep 2018 to 31 Dec 2025

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Evofem Biosciences, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2018 to 31 Dec 2025.
Evofem Biosciences, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was -115%, a 1.4% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Change (%)

Evofem Biosciences, Inc. Quarterly Debt-to-equity (%)

Period	Value	YoY Chg	Change %	Date
Q4 2025	-115%	+1.6%	+1.4%	31 Dec 2025
Q3 2025	-116%	-4.2%	-3.8%	30 Sep 2025
Q2 2025	-120%	-10%	-9.5%	30 Jun 2025
Q1 2025	-118%	-3.7%	-3.3%	31 Mar 2025
Q4 2024	-116%	+8.3%	+6.7%	31 Dec 2024
Q3 2024	-112%	+20%	+15%	30 Sep 2024
Q2 2024	-109%	+32%	+22%	30 Jun 2024
Q1 2024	-114%	+21%	+15%	31 Mar 2024
Q4 2023	-125%	+6.1%	+4.7%	31 Dec 2023
Q3 2023	-132%	-0.82%	-0.63%	30 Sep 2023
Q2 2023	-141%	-3.8%	-2.8%	30 Jun 2023
Q1 2023	-135%	+52%	+28%	31 Mar 2023
Q4 2022	-131%	+153%	+54%	31 Dec 2022
Q3 2022	-131%	+580%	+82%	30 Sep 2022
Q2 2022	-137%	-1188%	-113%	30 Jun 2022
Q1 2022	-187%	-554%	-151%	31 Mar 2022
Q4 2021	-283%	-519%	-220%	31 Dec 2021
Q3 2021	-711%	-843%	-637%	30 Sep 2021
Q2 2021	1051%	+951%	+956%	30 Jun 2021
Q1 2021	367%	+288%	+362%	31 Mar 2021
Q4 2020	236%	+68%	+40%	31 Dec 2020
Q3 2020	132%	-1082%	-89%	30 Sep 2020
Q2 2020	99%	+489%		30 Jun 2020
Q1 2020	79%	+264%		31 Mar 2020
Q4 2019	168%	+384%		31 Dec 2019
Q3 2019	1214%	+1271%		30 Sep 2019
Q2 2019	-390%			30 Jun 2019
Q1 2019	-185%			31 Mar 2019
Q4 2018	-217%			31 Dec 2018
Q3 2018	-57%			30 Sep 2018

* An asterisk sign (*) next to the value indicates that the value is likely invalid.